| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3307 | meridianin A | Novel Cell Death-Inducing Kinase Inhibitor with Enhanced Selectivity for Cyclin-Dependent Kinases; Antimalarial |
|
| DCC3308 | Meriolin 3 | Potent cell-permeable, ATP site-targeting inhibitor of CDKs |
|
| DCC3309 | Meriolin 5 | Potent cell-permeable, ATP site-targeting inhibitor of CDKs |
|
| DCC3310 | Merodantoin | Apoptosis inducer, triggering ROS dependent autophagy-associated apoptosis in a variety of human cancer cell lines and against mutant KRAS expressing cancer cells involving AKT-dependent ROS production |
|
| DCC3311 | Meso-dihydroguaiaretic Acid | LXR-α antagonist, inhibiting hepatic lipid accumulation by activating AMP-activated protein kinase in human HepG2 cells |
|
| DCC3312 | Mesterolone | Anabolic and androgenic agent |
|
| DCC3313 | Mesyl Salvinorin B | Novel selective and potent full KOP receptor agonist with fewer side effects (e.g., sedation or anhedonia) than classic KOP receptor |
|
| DCC3314 | Metabolex-36 | Novel selective GPR120 agonist |
|
| DCC3315 | Metamizole | Cyclooxygenase 3 (COX3) inhibitor, acting as a potent inductor of cytochrome P450 isoenzymes CYP2B6 and CYP3A4 |
|
| DCC3316 | Methocinnamox | Potent, long-lasting, and selective antagonist of morphine-mediated antinociception |
|
| DCC3317 | Methoxybrassinin | Natural potent anti-proliferative agent, inducing apoptotic cell death |
|
| DCC3318 | Methoxyluteolin | Inhibitor of pro-inflammatory mediator release from mast cells |
|
| DCC3319 | Methyl 6-bromo-1h-indazole-4-carboxylate | Useful pharmaceutical building block |
|
| DCC3320 | Methyl Meso-(meta-pyridinium) Bodipy | Novel photosensitizer as a photodynamic antimicrobial agent against Staphylococcus aureus, Escherichia coli, Candida albicans, and Methicillin-resistant S. aureus (MRSA) |
|
| DCC3321 | Methyl Streptonigrin | Novel inhibitor of ABCG2 transporter function |
|
| DCC3322 | Methylaervine Featured | Natural antifungal agent, significantly inducing lipid peroxidation, activating the antioxidant enzymes, and exhibiting effective activity against F. solani (EC50 = 10.56 µM) |
|
| DCC3323 | Methylene Quinuclidinone | Metablite of PRIMA-1 and APR-246, covalently binding to cysteine residues in mutant p53 and wild type p53, and being increased in unfolded p53, inducing massive apoptosis in p53 null tumor cells |
|
| DCC3324 | Methylhonokiol | Novel Class of Cannabinoid CB2 Receptor Inverse Agonist |
|
| DCC3325 | Methylnaltrexone Iodide | Peripherally restricted μ-opioid antagonist |
|
| DCC3326 | Met-in-3s | Highly Selective Class II MET Inhibitor |
|
| DCC3327 | Metoclopramide Hydrochloride | Dopamine D2 antagonist, antiemetic |
|
| DCC3328 | Metocurine | Non-depolarizing muscle relaxant |
|
| DCC3329 | Metrizoate Calcium | Radiographic Contrast Agent |
|
| DCC3330 | Mfn103 | Novel Dual Fluorescent and Magnetic Resonance False Neurotransmitter |
|
| DCC3331 | Mg2-1812 | Novel potent negative allosteric modulator (NAM) of mGlu2 |
|
| DCC3332 | Mg-277 | Novel potent inhibitor of the p53-MDM2 interaction with an IC50 value of 67.5 nmol/L, against acute leukemia cell lines with different p53 status and was much less effective in inducing MDM2 degradation |
|
| DC3333 | mG2N001 Featured | mG2N001 is a potent negative allosteric modulator (NAM) of metabotropic glutamate receptor 2 (mGluR2) with IC50 of 93 nM. |
|
| DCC3334 | Mgcd516 | Novel, multi-targeted kinase inhibitor, demonstrating potent inhibition of Trk, RET and DDR, in addition to Met, Axl and VEGFRs |
|
| DCC3335 | Mgs-0028 | Selective metabotropic glutamate 2/3 receptor agonist |
|
| DCC3336 | Mgs-0039 | Potent and orally active group II mGluR antagonist with antidepressant-like potential |
|
